Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma

Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis. Following the publication of the AVERT clinical study, Apixaban is strongly recommended as a prophylactic treatment option for patients with cancer, based on high quality of evidence and a favorable efficacy/safety profile. A multicenter and ancillary study - APIXABOR - that measured the plasmatic concentration of Apixaban in patients with MM and treated with preventive dose has been conducted. The peak drug concentration was superior in MM plasma, as com

Trial Details

NCT ID
NCT06474182
Phase
NA
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Blood sampling
  • Apixaban
Locations (sample)
  • Saint-Etienne, France|45.43389,4.39

Key Eligibility Criteria

  • Age ≥ 18 years old,
  • Signed informed consent,
  • Patient covered by a social security scheme.
  • Group 1 : patient with a diagnosis of de novo multiple myeloma, with an indication of thromboprophylaxis with Apixaban,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →